期刊
CANADIAN JOURNAL OF CARDIOLOGY
卷 38, 期 5, 页码 588-600出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.cjca.2022.01.026
关键词
-
资金
- Canadian Institutes of Health Research [FRN: 175150]
Peripheral artery disease is a manifestation of atherosclerosis, and patients have a high risk of vascular complications. Inflammation plays a significant role in the development of atherosclerosis, and anti-inflammatory agents can be used as an additional approach to reduce complications.
Peripheral artery disease is 1 of 3 major clinical manifestations of atherosclerosis, the other 2 being coronary artery and cerebrovascular disease. Despite progress in surgery, antithrombotic therapy and therapies that modify conventional risk factors (lipid-, blood pressure-, and glucose-lowering interventions), patients with peripheral artery disease have an unacceptably high risk of vascular complications. Additional strategies to reduce this residual risk are needed. The accumulated evidence that inflammation plays an important role in the pathogenesis of atherosclerosis has spurred recent efforts to evaluate anti-inflammatory agents as an additional therapeutic approach for atherothrombosis prevention and treatment. In this review, we examine the evidence supporting the role of inflammation in atherosclerosis, review recent trials of anti-inflammatory approaches to reduce cardiovascular complications, and offer insights into the opportunities for novel anti-inflammatory strategies to reduce the burden of cardiovascular and limb complications in patients with peripheral artery disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据